Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Ruxolitinib in Estrogen Receptor Positive Breast Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Abramson Cancer Center of the University of Pennsylvania
ClinicalTrials.gov Identifier:
NCT01594216
First received: May 7, 2012
Last updated: September 23, 2016
Last verified: September 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: No date given
  Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)